drugset / Trial / NCT04187443
MS-553 in Diabetic Retinopathy Patients With Central Involved Macular Edema
Phase 1
Recruiting
45 enrolled
Shenzhen MingSight Relin Pharmaceuticals Co., Ltd.
Fountain Medical Development Co., Ltd. · collab
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is an open label dose-escalation study to evaluate the safety and treatment benefits of MS-553 in treatment-naive diabetic retinopathy patients with central involved macular edema. Fifteen subjects with diabetic macular edema will be enrolled into each of three dose cohorts and will receive oral administration of MS-553 for 8 weeks.
Timeline
- Start
- 2020-06-02
- Primary completion
- 2026-10-30
- Completion
- 2026-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | MS-553 | Unknown | — | Oral |